Amylyx Pharmaceuticals (AMLX) Change in Acquisitions & Divestments (2022 - 2026)

Amylyx Pharmaceuticals' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $60.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments changed 0.0% year-over-year to $60.0 million in Q1 2026; TTM through Mar 2026 was $246.0 million, a 25.45% decrease from a year earlier, with the FY2025 full-year figure at $246.0 million, down 28.49% from the prior year.
• Change in Acquisitions & Divestments steadied at $60.0 million in Q1 2026 per AMLX's latest filing, from $60.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $147.9 million in Q4 2023 and bottomed at $24.9 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $64.0 million (2025), against an average of $72.0 million.
• Across the five-year window, Change in Acquisitions & Divestments soared 335.06% in 2023 and slumped 56.06% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $34.0 million in 2022, then surged by 335.06% to $147.9 million in 2023, then slumped by 56.06% to $65.0 million in 2024, then dropped by 7.69% to $60.0 million in 2025, then changed by 0.0% to $60.0 million in 2026.
• Per Business Quant, the three latest AMLX Change in Acquisitions & Divestments figures stand at $60.0 million (Q1 2026), $60.0 million (Q4 2025), and $64.0 million (Q3 2025).